market product solut
diagnost life scienc research market
requir disclosur end report
downgrad neutral
view current cl king meet event calendar coverag univers
launch coverag bio-rad laboratori year half ago
premis compani oper margin would expand upon
complet enterpris resourc plan erp implement
coupl cosmet low earn consequ low discount stock
price creat buy opportun trade massiv discount
earn potenti stock sinc initi think
hidden value/under-earn arbitrag stori longer hold addit
competit threat identifi week agbt confer includ
genom chromium ilmna iseq give us addit
concern bio-rad forward growth rate
hidden valu still appli know thing
cash land locat san francisco bay area larg invest
sartoriu held cost bio-rad stock doesnt screen well consensu
number chang modestli yet stock
sinc first initi coverag think due valuat
updat valuat adjust model reflect tax reform move
valuat see peak oper margin think
achiev ep use multipl discount
back two year plu add cash invest sartoriu get
price current price dont think there enough upsid
justifi buy rate
illumina iseq spoke coupl key opinion leader kol agbt
told us new iseq obviou method replac
qpcr mani applic analyst event confer
compani hide intent attack qpcr market list
price less per-run cost less kol
contact convinc instrument would eventu replac qpcr
although bio-rad doesnt break revenu estim qpcr
busi
singl cell stall found limit interest bio-rad ddseq
anyon agbt one kol spoke said price
genom instrument doesnt featur believ better
think singl cell opportun import driver achiev bio-
rad long-term growth rate without instrument contribut
growth compani might end grow closer
could wrong valuation-wis bio-rad go get major
currenc tailwind addit compani yet announc corpor
tax rate could give stock anoth leg although think stock
alreadi seen valuat realiz still rather cheap stock
less earn ad back cash sartoriu
could wrong competition-wis adopt iseq
qpcr like slow bio-rad could affect
minim final pick data suggest genom
run away singl cell market bio-rad could perhap lower
ddseq price product refresh bio-rad genom involv
multipl patent disput could potenti chang competit
model keep revenu number
rais ep estim reflect tax reform respect
ep forecast go vs street
vs street
abil cut cost
chang health care industry/regul
failur protect ip patent
lab consolid europ
page
